StockData
SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Scienture Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.92−0.44 (-13.10%)

Close on Oct 19, 2026

Market cap
$115.68M
P/E (TTM)
–
Dividend yield
–

Scienture Holdings, Inc. revenue by segment

By business segment

RevenueQ2 26Q1 26Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q4 23Q3 23Q2 23Q1 23% of revenueYoY
Trxade, Inc.[Member]––––––––$1.74M$1.66M$1.56M$1.44M––
Community Specialty Pharmacy LLC [Member]––––––––––$325.81K$311.26K––
Integra Pharma LLC [Member]––––––––––$366.53K$476.36K––
Other Segments [Member]––––––––$905–$1.90K$16.96K––
Integra [Member]–––$10.26K$53.08K$64.86K$18.70K–$128.66K$392.29K$366.53K$476.36K––
Unallocated Segments [Member]–––––––––––$16.96K––

By product or service

RevenueQ2 26Q1 26Q2 25Q1 25Q4 24Q3 24Q2 24Q1 24Q4 23Q3 23Q2 23Q1 23% of revenueYoY
Losartan Potassium Oral Suspension [Member]$343.64K$56.33K––––––––––100.0%–
Product Revenue [Member]–––––$64.86K$18.70K–$615.68K$392.29K$366.53K$476.36K––
Service Revenue [Member]––––––––$1.74M$1.66M–$16.96K––
Pharmaceutical Product Resale [Member]––$0$10.26K––––––––––

By region

From the segment and revenue-disaggregation notes of Scienture's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.